Cognizance of schizophrenia : a profound insight into the psyche / / Indranath Chatterjee, editor

• Pubblicazione: Singapore : , : Springer, , [2023]; ©2023
• Descrizione fisica: 1 online resource (313 pages)
• Disciplina: 616.8980072
• Soggetto topico: Schizophrenia - Psychological aspects; Schizophrenia
• Persona (resp. second.): ChatterjeeIndranath
• Nota di bibliografia: Includes bibliographical references.
• Nota di contenuto: Intro -- Preface -- Contents -- Chapter 1: Understanding Schizophrenia: Introductory Aspect of the Mental Disorder from Various Perspectives -- 1.1 Introduction -- 1.2 Symptoms of Schizophrenia -- 1.2.1 Positive Symptoms -- 1.2.2 Negative Symptoms -- 1.2.3 Mixed and Cognitive Symptoms -- 1.3 Causes and Diagnosis of Schizophrenia -- 1.4 Perceptions on Schizophrenia -- 1.4.1 Negative Perceptions of Schizophrenia -- 1.4.2 Perceptions of Schizophrenia in Later Life -- 1.4.3 Psychodynamic Perspectives of Schizophrenia -- 1.4.4 Cognitive Perspective of Schizophrenia -- 1.4.5 Humanistic Perspectives of Schizophrenia -- 1.4.6 Sociocultural Perspective of Schizophrenia -- 1.4.7 Cross-Cultural Perspectives and Influences of Culture on Schizophrenia -- 1.4.8 Cognitive-Behavioral Perspective Schizophrenia -- 1.5 Recent Advancement in Schizophrenia -- 1.6 Conclusions -- References -- Chapter 2: Genetic Mutations and Alternative Splicing in Schizophrenia -- 2.1 What Is Neurogenetics? Related Disease and Disorder -- 2.1.1 Neurogenetic Diseases -- 2.1.2 Neurogenetic Disorders -- 2.2 Schizophrenia and Genetics -- 2.2.1 Schizophrenia -- 2.2.2 Genetics -- 2.3 Genetic Mutations and How They Are Responsible to Cause Schizophrenia -- 2.4 RNA Splicing and Miss-Splicing (Introduction) -- 2.5 Genes Involved in RNA Miss-Splicing to Increase Schizophrenia Risk -- 2.6 How RNA Miss-Splicing (Alternative Splicing) Related to Schizophrenia? -- 2.7 Treatment -- 2.7.1 Medication -- 2.7.2 Psychological -- 2.8 Future Goal and Discussion -- References -- Chapter 3: Understanding the Chemical Interactions in the Brain of Schizophrenia Patients -- 3.1 Introduction -- 3.2 Brain: Its Parts -- 3.2.1 Hindbrain -- 3.2.2 Midbrain -- 3.2.3 Forebrain -- 3.3 Schizophrenia: Its Neurochemistry -- 3.3.1 Dopamine and Schizophrenia -- 3.3.2 Serotonin and Schizophrenia. ; 3.3.3 Glutamate and Schizophrenia -- 3.3.4 GABA and Schizophrenia -- 3.3.5 Other Neurotransmitters and Schizophrenia -- 3.4 Neuroanatomical Changes During Schizophrenia -- 3.5 Conclusion -- References -- Chapter 4: A Diagnostic Perspective of Schizophrenia: From Past to Present -- 4.1 Introduction -- 4.2 Clinical Manifestations -- 4.2.1 Positive -- 4.2.2 Negative -- 4.2.3 Cognitive -- 4.3 Rationale -- 4.4 Diagnosis -- 4.5 Magnetic Resonance Spectroscopy (MRS) for Schizophrenia -- 4.6 Molecular Pathology of Schizophrenia -- 4.7 Neuroimaging in Schizophrenia: Advancement in Technique -- 4.8 Computed Tomography (CT Scan)Analysis -- 4.8.1 Magnetic Resonance Imaging -- 4.9 Psychometric Analysis -- 4.9.1 Cognitive Analysis -- 4.9.2 Clinical Observations and Analysis -- 4.10 Psychological -- 4.10.1 Stressors Presence -- 4.10.2 Presence of External Stress -- 4.10.3 Presence of Internal Stress -- 4.10.4 Stressors Appraisal -- 4.10.5 External Stress Appraisal -- 4.10.6 Internal Stress Appraisal -- 4.10.7 Impairment of Cognitive Processes and Cognitive Biases -- 4.10.8 Reasons and Problem-Solving of Biases -- 4.10.9 Related to Memory and Memory Retrieval Deficiencies -- 4.11 Questionnaire -- 4.11.1 Positive and Negative Symptoms Questionnaire -- 4.12 Conclusion and Scope of Future Work -- References -- Chapter 5: Is It Schizophrenia or Not? Different Biological Characterization -- 5.1 Introduction -- 5.2 Schizophrenia -- 5.3 Alzheimer´s Disease -- 5.4 Parkinson Disease (PD) -- 5.5 Chronic Depression (CD) -- 5.6 Bi-Polar Disorder -- 5.7 Conclusion -- References -- Chapter 6: Neurobiological Aspects of Schizophrenia and Relationship Between Neurological Disorders: Depression, Anxiety, and ... -- 6.1 Introduction -- 6.2 Neurobiology of a Brain and How Brain Works -- 6.2.1 Brain -- 6.2.2 What Is Neurobiology? -- 6.2.3 Nervous System. ; 6.2.3.1 Gray Matter and White Matter -- 6.2.4 Brain and Functions -- 6.2.4.1 Cerebrum -- 6.2.4.2 Brain Stem -- 6.2.4.3 Cerebellum -- 6.3 What Is Schizophrenia and How It Changes the Structural Integrity of the Brain? -- 6.3.1 Schizophrenia -- 6.3.1.1 Symptoms -- 6.3.1.2 Reasons for Schizophrenia -- 6.3.2 Changes the Structure Integrity of the Brain -- 6.4 How Schizophrenia Brain Acts as Disorder Neurobiologically -- 6.4.1 Neurobiology of Schizophrenia Brain -- 6.5 What Depression and Anxiety Affect Neurobiologically -- 6.5.1 Depression and Anxiety -- 6.5.1.1 Depression -- 6.5.1.2 Anxiety Disorder -- 6.6 How Epilepsy and Schizophrenia Connected Depression and Anxiety Disorder -- 6.6.1 Epilepsy -- 6.6.2 Anxiety Disorder and Depression and Epilepsy -- References -- Chapter 7: Clinical Treatment Available for Schizophrenia -- 7.1 Introduction -- 7.2 Assessment and Evaluation -- 7.3 Decision Regarding Treatment Setting -- 7.4 Phases of Treatment -- 7.4.1 Acute Phase of Treatment -- 7.4.2 Continuation Phase of Treatment -- 7.4.3 Maintenance Phase of Treatment -- 7.5 Options Available for Treatment -- 7.5.1 Pharmacological Management -- 7.5.1.1 Chemical Classification of Antipsychotic -- 7.5.1.2 Generation and Mechanism-Wise Classification of Antipsychotic -- 7.5.1.3 First-Generation Antipsychotics (FGAs) Mechanism of Action -- 7.5.1.4 Second-Generation Antipsychotics (SGAs) Mechanism of Action -- 7.5.1.5 Nobel Antipsychotic -- 7.5.1.6 Receptor Interactions of Antipsychotics (Stahl 2021) -- 7.5.1.6.1 Effect on Other Receptors of Antipsychotics -- 7.5.1.6.2 Effect on Other Systems of Antipsychotics -- 7.5.1.6.3 Other Side Effects -- 7.5.1.6.4 Interactions -- 7.5.1.7 Side Effects of Antipsychotics at a Glance -- 7.5.1.7.1 Tardive Dyskinesia (TD) -- 7.5.1.7.2 Neuroleptic Malignant Syndrome (NMS) -- 7.5.1.8 Management of NMS. ; 7.5.1.9 How to Select Antipsychotics -- 7.5.1.10 Selection of Route of Administration -- 7.5.1.11 Long-Acting/Depot Injections Preparations -- 7.5.1.12 Adjunctive Medications Along with Antipsychotics -- 7.5.2 Electroconvulsive Therapy (ECT) -- 7.5.2.1 Mechanism of Action of ECT -- 7.5.2.2 Indications for ECT -- 7.5.2.3 Number of Sessions for ECT -- 7.5.2.4 Contraindications of ECT -- 7.5.2.5 Relative Contraindications of ECT -- 7.5.3 Psychological Management (Kreyenbuhl et al. 2010) -- 7.5.3.1 Psychoeducation for Patients and Caregivers -- 7.5.3.2 Family Intervention (Grover et al. 2017) -- 7.5.3.2.1 Components of Family Intervention -- 7.5.3.2.2 Advantages of Family Intervention -- 7.5.3.3 Cognitive Behavioural Therapy -- 7.5.3.3.1 Components of CBT -- 7.5.3.3.2 Steps of CBT -- 7.5.3.4 Social Skill Training -- 7.5.3.4.1 Components of Social Skill Training -- 7.5.3.4.2 Seven Blocks of Social Skill Training -- 7.5.3.4.3 Commonly Used Methods -- 7.5.3.5 Assertive Community Treatment -- 7.5.3.5.1 Elements of Assertive Community Treatment -- 7.5.3.5.2 Outcome of Assertive Community Treatment -- 7.5.3.6 Token Economy -- 7.5.3.6.1 Advantages of Token Economy -- 7.5.3.7 Vocational Rehabilitation -- 7.5.3.7.1 Advantages of Vocational Rehabilitation -- 7.6 Conclusion -- References -- Chapter 8: Insights into the Neuro-Pharmacological Treatment of Schizophrenia: Past, Present, and Future -- 8.1 Introduction -- 8.1.1 Definition of Schizophrenia -- 8.2 Development of Schizophrenia -- 8.3 Cause of Schizophrenia -- 8.4 Onset of Schizophrenia and Related Symptoms -- 8.5 Treatments for Schizophrenia -- 8.6 Neuropharmacological Treatments for Schizophrenia -- 8.6.1 Historical Evolution -- 8.6.2 Antipsychotic Drugs (Neuroleptics) -- 8.7 Mechanism of Action of Neuroleptics (Central Nervous System) -- 8.7.1 Drawbacks of Traditional Neuroleptics. ; 8.8 Cutting-Edge Alternatives -- 8.9 Conclusion -- References -- Chapter 9: Managing Schizophrenia: A Challenge for Physicians -- 9.1 Introduction -- 9.2 Pathomechanisms of Schizophrenia -- 9.2.1 Dopaminergic Hypothesis -- 9.2.2 Glutamatergic Hypothesis -- 9.2.3 Other Aminergic Receptors -- 9.2.4 GABAergic Hypothesis -- 9.2.5 Other Hypotheses -- 9.3 Clinical Management of Schizophrenia -- 9.3.1 Pharmacotherapy -- 9.3.1.1 First-Generation Antipsychotics (FGAs) -- Mechanism of Action -- Adverse Effects Profile -- Chlorpromazine Equivalent Dose -- 9.3.1.2 Second-Generation Antipsychotics (SGAs) -- Mechanism of Action -- Clozapine: The Most Atypical Antipsychotic -- 9.3.1.3 Treatment-Resistant Schizophrenia -- Risperidone -- Adverse Effects Profile -- 9.3.1.4 Third-Generation Antipsychotics -- Mechanism of Action -- Adverse Effects Profile -- 9.3.2 Non-pharmacotherapy -- 9.3.2.1 Psychotherapy -- Cognitive Behavioral Therapy -- 9.3.2.2 Electroconvulsive Therapy -- 9.3.2.3 Transcranial Magnetic Stimulation Therapy -- 9.4 Augmentation Strategies -- 9.5 Phase-Wise Management of Schizophrenia -- 9.5.1 Management of First-Episode Psychosis -- 9.5.1.1 Psychotherapy -- 9.5.1.2 Pharmacotherapy -- 9.5.2 Management of Acute Phase -- 9.6 Maintenance Phase of Schizophrenia -- 9.7 Dosing Regimens for Antipsychotics -- 9.8 Antipsychotics in Pregnancy -- 9.9 Antipsychotic Withdrawal -- 9.9.1 Neuroleptic Malignant Syndrome (NMS) -- 9.10 Future Research Recommendations -- References -- Chapter 10: Pharmacotherapy and Emerging Treatment Strategies for Schizophrenia -- 10.1 Introduction -- 10.2 First-Generation Antipsychotics (FGAs) -- 10.2.1 Examples of the First-Generation Antipsychotics -- 10.3 Second-Generation Antipsychotics -- 10.3.1 Clozapine -- 10.3.2 Olanzapine -- 10.3.3 Risperidone -- 10.3.4 Paliperidone -- 10.3.5 Ziprasidone -- 10.3.6 Quetiapine. ; 10.3.7 Aripiprazole.
• Titolo autorizzato: Cognizance of Schizophrenia
• ISBN: 9789811970221; 9789811970214
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910639885703321
• Lo trovi qui: Univ. Federico II